Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.

摘要: Abstract Purpose In Europe, pancreatic cancer (PC) accounts for approximately 2.6% of all new cases and is the fourth leading cause cancer-related death. Despite substantial morbidity mortality, limited data are available describing real-world treatment patterns health care resource use in any European country. We evaluated PC-related associated among patients with metastatic PC United Kingdom France. Methods One hundred three oncology specialists (53 France 50 Kingdom) abstracted from medical records 400 whom they treated PC. Eligible had a diagnosis at age 18 years or older between January 1, 2009, December 31, 2012; ≥3 months follow-up time beginning diagnosis; received least 1 cancer-directed therapy disease. Information on patient demographics, Eastern Cooperative Oncology Group performance status, location primary tumor, presence comorbidities, adverse events, complications were collected. Data treatments supportive measures evaluated. All analyses descriptive. Findings Approximately two thirds men, median disease was 62.2 years. Nearly (97.3%) chemotherapy to treat disease, 9.3% radiation therapy, 7.8% targeted therapy. Overall, most frequently administered first-line regimens gemcitabine alone (46.0%), combination regimen consisting oxaliplatin, irinotecan, fluorouracil, leucovorin (FOLFIRINOX; 20.1%); gemcitabine/capecitabine (10.8%); gemcitabine/oxaliplatin (9.5%). 40% 15% second-line systemic whereas 20% 3.4% third-line 52.5% experienced one complication More than ≥1 office visit unrelated administration, 54.0% inpatient hospitalization, 36.8% emergency department visit, 25.3% pain management clinic visit. A total 26.5% 42.5% entered hospice long-term care. Implications This study provides new, detailed information settings 2 countries. small proportion >1 line which likely due aggressiveness this lack effective therapeutic options.